Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral and anticancer activity, targeting multiple potential indications, including gastrointestinal acute radiation syndrome (GI-ARS), viral infections such as COVID-19, Ebola virus disease and additional viruses as part of pandemic preparedness, several cancers and diabetes and obesity-related disorders.
Read more
|
Gastrointestinal acute radiation syndrome
Opaganib is being evaluated as a potential new therapeutic approach to mitigate gastrointestinal acute radiation syndrome (GI-ARS) in collaboration with the NIAID RNCP following the FDA Animal Rule regulatory pathway.
Read more
|
Acute respiratory distress syndrome (ARDS), including COVID-19 and influenza
Phase 2/3 COVID-19 (ARDS)
Opaganib is being evaluated for its potential to treat acute respiratory distress syndrome (ARDS) caused by viruses such as COVID-19 and influenza. Data from the global Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia offer a compelling rationale for further investigation into opaganib’s potential in treating virus-induced ARDS, potentially supporting a Phase 2/3 study in this indication.
Read more
|
Opaganib is being evaluated as a potential treatment for Ebola virus disease in collaboration with the U.S. Army and BARDA. Supported by initial funding from the BARDA research and development contract, the collaboration seeks to advance opaganib’s development to combat infections and control Ebola virus disease outbreaks.
Read more
|
Opaganib completed a single-arm Phase 2a clinical study in patients with advanced, unresectable cholangiocarcinoma and has been granted FDA Orphan Drug Designation for this indication.
Read more
|
Opaganib is undergoing a Phase 2 study in combination with Bayer’s darolutamide in men with metastatic castration-resistant prostate cancer (mCRPC) and has completed a prior investigator-sponsored Phase 2 study evaluating its safety and efficacy in progressive mCRPC treated with androgen-signaling blockers, abiraterone or enzalutamide.
Read more
|
RHB-204 is an investigational, proprietary, fixed-dose, orally administered, antibiotic combination therapy targeting Crohn’s disease in Mycobacterium avium subspecies paratuberculosis-positive (MAP+) patients. It is a next-generation formulation of RHB-104, which demonstrated positive results in a Phase 3 Crohn’s disease study, meeting both primary and secondary endpoints. RHB-204 combines the same antimicrobial agents as RHB-104 with potent intracellular, anti-mycobacterial, and anti-inflammatory properties, but with an optimized dosing profile designed to support enhanced tolerability, safety and adherence.
RHB-204 also has potential for the treatment of pulmonary nontuberculous mycobacterial (NTM) disease caused by Mycobacterium avium complex (MAC).
Read more
|
An innovative Phase 2 study of RHB-204 is planned in patients with moderate to severe Crohn’s disease who test positive for Mycobacterium avium subspecies paratuberculosis (MAP).
Read more
|
A previously ongoing U.S. Phase 3 study evaluating RHB-204 for the treatment of pulmonary nontuberculous mycobacterial (NTM) disease caused by Mycobacterium avium complex (MAC) was terminated due to a low patient accrual rate.
Read more
|
RHB-107 (INN: upamostat) is a first-in-class, once-daily, orally administered serine protease inhibitor targeting multiple potential indications, including viral infections such as COVID-19 & Ebola virus disease, oncology and inflammatory gastrointestinal diseases.
Read more
|
RHB-107 is being evaluated in the ongoing U.S. Government-supported, Phase 2 platform trial (PROTECT study) for early COVID-19 outpatient treatment.
RHB-107 has already completed a positive U.S. Phase 2 study in non-hospitalized symptomatic COVID-19 patients, which evaluated the safety and tolerability profile of RHB-107, along with efficacy signals.
Read more
|
RHB-107 is being evaluated as a potential treatment for Ebola virus disease in collaboration with the U.S. Army.
Read more
|
RHB-102 is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet
formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, targeting potential
indications including oncology support, acute gastroenteritis and gastritis, and IBS-D at two
dose strengths, 12mg and 24mg.
RHB-102 is being developed by Hyloris Pharmaceuticals outside of North America. Learn more.
Read more
|
Gastroenteritis and gastritis
Completed positive U.S. Phase 3 study
RHB-102 (24 mg) successfully completed a randomized, double-blind, placebo-controlled U.S.
Phase 3 study meeting the primary outcome measure, demonstrating its safety and efficacy in
the treatment of acute gastroenteritis and gastritis.
RHB-102 is being developed by Hyloris Pharmaceuticals outside of North America. Learn more.
Read more
|
IBS-D
Completed positive U.S. Phase 2 study
RHB-102 (12 mg) successfully completed a positive randomized, double-blind, placebo controlled U.S. Phase 2 study meeting the primary outcome measure, demonstrating its safety and efficacy in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
RHB-102 is being developed by Hyloris Pharmaceuticals outside of North America. Learn more.
Read more
|
Oncology Support
Comparative bioavailability studies
RHB-102 (24 mg) is in development for the management of chemotherapy and radiotherapy induced nausea and vomiting (also referred to as CINV and RINV).
RHB-102 is being developed by Hyloris Pharmaceuticals outside of North America. Learn more.
Read more
|